Sundaram Preethi (CIK 1872422) reported 9 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-17). Recent activity: Sell CPRX (54,804 shares), Buy CPRX (6,667 shares), Sell CPRX (2,369 shares), Buy CPRX (6,855 shares), Sell CPRX (1,669 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Sell | 54,804 | $1.7M |
| 2025-12-30 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Buy | 6,667 | $0 |
| 2025-12-30 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Sell | 2,369 | $0 |
| 2025-12-10 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Buy | 6,855 | $0 |
| 2025-12-10 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Sell | 1,669 | $0 |
| 2025-11-24 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Buy | 5,603 | $0 |
| 2025-11-24 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Sell | 1,364 | $0 |
| 2025-06-12 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Sell | 2,324 | $61,377 |
| 2025-06-12 | CATALYST PHARMACEUTICALS, INC. (CPRX) | Chief Strategy Officer | Sell | 1,600 | $42,272 |
Source: SEC Form 4 filings · as of 2026-07-17